35Pharma

Part of GSK

CompanyCanada

35Pharma develops one asset, in phase 1 (HS235 in heart failure with preserved ejection fraction). Mostly protein or enzyme; based in Canada.

1
Asset
Furthest stage
Phase 1
2
Trials
0
Signals

Pipeline

1
  • HS235

    Ligand trap that inhibits activin receptor signaling.

    Phase 1, Protein or enzyme, heart failure with preserved ejection fraction, pulmonary arterial hypertension

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials2
  • Similar companies6

Intelligence